InsiderTrades.com logo
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
From Crypto Swap Profits   |   Ad
All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.
Register for the FREE Workshop Now & get $10 in Bitcoin
Arthur A. Levin net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Arthur Levin Biography and Net Worth

Insider of Avidity Biosciences
Arthur Levin is a key opinion leader in the RNA therapeutics field. He serves as the CSO at Avidity Biosciences. Previously, he held Senior levels positions at mRiragen, Santaris Pharma, and Ionis Pharmaceuticals. He played key roles in developing numerous of oligonucleotides including the first approved antisense drugs and the first microRNA-targeted therapeutic in clinical trials. He has three decades of experience in drug development from discovery through drug registration. Dr. Levin has published over 60 scientific articles and several of the most cited reviews in the field. He is on the scientific advisory boards of multiple institutions. Art received a doctorate in toxicology from the University of Rochester.

What is Arthur A. Levin's net worth?

The estimated net worth of Arthur A. Levin is at least $471,890.60 as of November 19th, 2024. Dr. Levin owns 14,830 shares of Avidity Biosciences stock worth more than $471,891 as of December 21st. This net worth evaluation does not reflect any other investments that Dr. Levin may own. Additionally, Dr. Levin receives a salary of $304,690.00 as Insider at Avidity Biosciences. Learn More about Arthur A. Levin's net worth.

How old is Arthur A. Levin?

Dr. Levin is currently 70 years old. There are 7 older executives and no younger executives at Avidity Biosciences. The oldest executive at Avidity Biosciences is Dr. Frank P. McCormick Ph.D., Scientific Founder & Member of Scientific Advisory Board, who is 74 years old. Learn More on Arthur A. Levin's age.

What is Arthur A. Levin's salary?

As the Insider of Avidity Biosciences, Inc., Dr. Levin earns $304,690.00 per year. There are 4 executives that earn more than Dr. Levin. The highest earning executive at Avidity Biosciences is Ms. Sarah Boyce, President, CEO & Director, who commands a salary of $998,880.00 per year. Learn More on Arthur A. Levin's salary.

How do I contact Arthur A. Levin?

The corporate mailing address for Dr. Levin and other Avidity Biosciences executives is 10975 N. TORREY PINES RD. SUITE 150, LA JOLLA CA, 92037. Avidity Biosciences can also be reached via phone at 858-401-7900 and via email at [email protected]. Learn More on Arthur A. Levin's contact information.

Has Arthur A. Levin been buying or selling shares of Avidity Biosciences?

Within the last three months, Arthur A. Levin has sold $373,114.76 in Avidity Biosciences stock. Most recently, Arthur A. Levin sold 3,323 shares of the business's stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $42.12, for a transaction totalling $139,964.76. Following the completion of the sale, the director now directly owns 14,830 shares of the company's stock, valued at $624,639.60. Learn More on Arthur A. Levin's trading history.

Who are Avidity Biosciences' active insiders?

Avidity Biosciences' insider roster includes Sarah Boyce (President & CEO), W. Flanagan (Insider), Arthur Levin (Insider), Michael MacLean (Chief Financial and Chief Business Officer), Teresa Mccarthy (Insider), and Tamar Thompson (Director). Learn More on Avidity Biosciences' active insiders.

Are insiders buying or selling shares of Avidity Biosciences?

During the last year, insiders at the biotechnology company sold shares 36 times. They sold a total of 988,429 shares worth more than $33,473,368.19. The most recent insider tranaction occured on December, 18th when insider W. Michael Flanagan sold 12,742 shares worth more than $416,153.72. Insiders at Avidity Biosciences own 3.7% of the company. Learn More about insider trades at Avidity Biosciences.

Information on this page was last updated on 12/18/2024.

Arthur A. Levin Insider Trading History at Avidity Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/19/2024Sell3,323$42.12$139,964.7614,830View SEC Filing Icon  
10/21/2024Sell5,000$46.63$233,150.0014,830View SEC Filing Icon  
9/19/2024Sell5,000$45.73$228,650.0014,830View SEC Filing Icon  
8/19/2024Sell5,000$45.19$225,950.0014,830View SEC Filing Icon  
7/19/2024Sell5,000$45.01$225,050.0014,830View SEC Filing Icon  
6/20/2024Sell5,000$37.59$187,950.0014,830View SEC Filing Icon  
6/12/2024Sell40,000$35.07$1,402,800.00213,872View SEC Filing Icon  
5/20/2024Sell5,000$29.90$149,500.0014,830View SEC Filing Icon  
4/19/2024Sell5,000$22.82$114,100.0014,830View SEC Filing Icon  
4/3/2024Sell20,000$27.11$542,200.00253,872View SEC Filing Icon  
3/12/2024Sell27,641$22.03$608,931.2314,830View SEC Filing Icon  
1/22/2024Sell1,859$10.13$18,831.6717,471View SEC Filing Icon  
2/14/2023Sell10,000$23.66$236,600.0019,330View SEC Filing Icon  
1/12/2023Sell10,000$22.00$220,000.001,330View SEC Filing Icon  
8/15/2022Sell62,498$22.12$1,382,455.761,330View SEC Filing Icon  
8/12/2022Sell14,003$22.00$308,066.001,330View SEC Filing Icon  
11/18/2021Sell25,000$27.89$697,250.00View SEC Filing Icon  
6/25/2021Sell20,100$28.12$565,212.001,430View SEC Filing Icon  
6/17/2021Sell200$27.75$5,550.001,530View SEC Filing Icon  
6/14/2021Sell14,003$25.92$362,957.76View SEC Filing Icon  
3/16/2021Sell4,600$27.87$128,202.002,625View SEC Filing Icon  
See Full Table

Arthur A. Levin Buying and Selling Activity at Avidity Biosciences

This chart shows Arthur A Levin's buying and selling at Avidity Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Avidity Biosciences Company Overview

Avidity Biosciences logo
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $31.82
Low: $30.85
High: $32.63

50 Day Range

MA: $42.38
Low: $30.70
High: $52.50

2 Week Range

Now: $31.82
Low: $8.49
High: $56.00

Volume

2,906,533 shs

Average Volume

1,316,742 shs

Market Capitalization

$3.80 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89
AI breakthrough about to upend industry
From Porter & Company   |   Ad
Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.
I urge you to watch it now.